Introduction
Methods
Search strategy
Study selection
Data extraction and statistical analysis
Results
Ref | Study | Case/ctrl | N | Age | % F | Chemokines tested | Assay method | Study design | Sample | NOS | AD/MCI diagnosis |
---|---|---|---|---|---|---|---|---|---|---|---|
[44] | Alsadany, 2013 | AD | 25 | 72.2 (5.9) | 56 | IL-8 | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 25 | 72.8 (4.1) | 52 | ||||||||
[45] | Andrés-Benito, 2020 | AD | 19 | 64 (8.6) | 82 | CXCL12 (SDF-1) | ELISA | Case–control | CSF | 7 | NR |
HC | 70 | 67 (10.6) | 81 | ||||||||
[46] | Blasko, 2006 | AD | 23 | 71.9 (9.6) | 65 | MCP-1 | ELISA | Case–control | CSF | 7 | NINCDS-ADRDA |
HC | 27 | 66.9 (9.4) | 52 | ||||||||
[47] | Boccardi, 2019 | MCI | 73 | 77.5 (6.3) | 61.6 | MCP-1 | ELISA | Case–control | Serum | 7 | Petersen |
HC | 87 | 75.9 (9) | 59.8 | ||||||||
[48] | Bonaccorso, 1998 | AD | 15 | 55.2 (22.2) | 47 | IL-8 | ELISA | Case–control | Plasma | 7 | DSM-III-R |
HC | 31 | 75.6 (9.1) | 55 | ||||||||
[49] | Bonotis, 2008 | AD | 49 | 75.8 (6.2) | 57.1 | IL-8 | ELISA | Case–control | Serum | 7 | NINCDS-ADRDA |
HC | 21 | 71.2 (4.4) | 52.4 | ||||||||
[40] | Björkqvist, 2012 | AD | 142 | 76 (56–87) | 28 | CCL18, CCL5, CCL7, CXCL8, CCL15 | Quantibody Array | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 174 | 74 (62–99) | 67 | ||||||||
[32] | Choi, 2008 | AD | 11 | 73.5 (4.0) | 81.8 | IL-8, IP-10, MCP-1 (+ CSF), RANTES, Eotaxin, MIP-1α | Luminex xMAP™ | Case–control | CSF/serum | 7 | NINCDS-ADRDA |
HC | 13 | 68.5 (7.2) | 61.5 | ||||||||
[50] | Corrêa, 2011 | AD | 22 | 74.7 (10.2) | 77.3 | MCP-1, CXCL8, CXCL10 | ELISA | Case–control | CSF | 7 | NINCDS-ADRDA |
HC | 27 | 64.4 (11.1) | 44.5 | ||||||||
[51] | Corsi, 2011 | AD | 70 | 75.6 (7.2) | 61 | IL-8, MCP-1 | Biochip Array | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 6 | 73.4 (1.1) | 67 | ||||||||
[52] | Delaby, 2015 | AD | 24 | 70.8 (8.7) | 52 | IL-8, MCP-1, MIP-1β, MIP-3β, RANTES, GRO-α, GRO-γ | ECL/ELISA | Case–control | CSF/ serum | 7 | NINCDS-ADRDA |
HC | 31 | 66.6 (13.3) | 67 | ||||||||
[53] | Dong, 2018 | AD | 26 | 66.6 (52–83) | 69.2 | IL-8, MCP-1 | Luminex xMAP™ | Prospective cohort | Serum | 8 | NINCDS-ADRDA |
MCI | 16 | 71.0 (53–84) | 50 | ||||||||
HC | 22 | 71.6 (60–88) | 72.7 | ||||||||
[54] | Faura, 2020 | AD | 36 | 77 (72.5–83) | 66.7 | CCL23 | ELISA | Cross-section | Serum | 8 | NINCDS-ADRDA |
HC | 11 | 77 (72.5–83) | 66.7 | ||||||||
[55] | Fenoglio, 2004 | AD | 269 | 75 (51–101) | 71 | MCP-1 | ELISA | Case–control | Serum | 7 | NINCDS-ADRDA |
HC | 203 | 72 (46–96) | 54.2 | ||||||||
[56] | Galimberti, 2006 | AD | 94 | 79.1 (7) | 75 | MCP-1 | ELISA | Case–control | Serum | 7 | NINCDS-ADRDA |
MCI | 48 | 74.7 (6.8) | 60 | ||||||||
HC | 24 | 71.5 (9.8) | 29 | ||||||||
[57] | Galimberti, 2006 | AD | 22 | 59.4 (4.2) | 59 | IP-10, IL-8, MCP-1 | ELISA | Case–control | CSF | 7 | NINCDS-ADRDA |
MCI | 38 | 68 (10.5) | 63 | ||||||||
HC | 41 | 64 (29.5) | 63 | ||||||||
[58] | Gongora-River, 2019 | AD | 29 | 75.3 (7.3) | 82.8 | CCL27, CXCL12, CCL7, CXCL9 | Luminex xMAP™ | Case–control | Serum | 8 | NINCDS-ADRDA |
HC | 49 | 72.85 (6.6) | 75.5 | ||||||||
[59] | Grewal, 2016 | MCI | 45 | 76.2 (8.1) | 100 | MCP-1, eotaxin | Luminex xMAP™ | Case–control | Plasma | 7 | DSM-V |
HC | 30 | 72.97 (8.8) | 100 | ||||||||
[60] | Gupta, 2017 | AD | 92 | 77.0 (7.4) | 57 | CCL1 | ECL | Cross-section | Plasma | 7 | NINCDS-ADRDA |
MCI | 65 | 74.8 (7.5) | 55 | ||||||||
HC | 554 | 69.79 (6.5) | 60 | ||||||||
[61] | Hazen, 2020 | AD | 154 | 74.9 (7.4) | 58.4 | CCL2, CCL4 | Luminex xMAP™ | Prospective cohort | Serum | 7 | NINCDS-ADRDA |
MCI | 88 | 71.3 (10.3) | 47.7 | ||||||||
[62] | He, 2017 | AD | 19 | 71.1 (35.4) | 47.4 | CCL1, CCL2, CCL3, CCL4, CCL7, CCL8, CCL11, CCL13, CCL15, CCL17, CCL19, CCL20, CCL21, CCL22, CCL24, CCL26, CCL27, CX3CL1, CXCL1, CXCL5, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL8 | Luminex xMAP™ | Case–control | Plasma | 6 | NINCDS-ADRDA |
HC | 19 | 70.2 (24.1) | 47.4 | ||||||||
[63] | Hesse, 2016 | AD | 41/36 | 68(9.5)/68 (5.9) | 71/69 | IL-8 | ECL | Case–control | CSF /serum | 7 | NINCDS-ADRDA |
HC | 23/24 | 69(11.6)/70(9.5) | 57/50 | ||||||||
[28] | Hochstrasser, 2011 | AD | 92 | 78.8 (7.1) | 77.2 | CCL4, CCL2, CCL22, CCL15, CXCL9 | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA /Petersen |
MCI | 67 | 73.8 (8) | 65.7 | ||||||||
HC | 40 | 72.2 (6.3) | 52.5 | ||||||||
[25] | Kim, 2008 | AD | 51 | 78.2 (6.1) | 82.4 | CX3CL1 | ELISA | Cross-section | Plasma | 8 | NINCDS-ADRDA |
MCI | 51 | 74.6 (7.0) | 80.4 | ||||||||
HC | 57 | 70.5 (3.8) | 70.2 | ||||||||
[64] | Kim, 2011 | AD | 18 | 75.9 (6) | 50 | MCP-1, IL-8 | ELISA | Cross-section | Plasma | 7 | NINCDS-ADRDA |
MCI | 20 | 76.1 (2.8) | 45 | ||||||||
HC | 21 | 75.5 (1.3) | 52.4 | ||||||||
[65] | King, 2019 | MCI | 38 | 75.6 (1.2) | 34 | IL-8 | ECL | Cross-section | Plasma | 7 | NIA-AA |
HC | 20 | 75.9 (1.6) | 20 | ||||||||
[66] | Kulczyńska -Przybik, 2020 | AD | 42 | 72.5 (51–89) | NR | CCL2, CX3CL1 | ELISA | Cross-section | CSF /serum | 7 | NIA-AA |
MCI | 18 | 72.5 (51–89) | NR | ||||||||
HC | 20 | 72.5 (51–89) | NR | ||||||||
[67] | Laske, 2008 | AD | 30 | 70.5 (8.2) | 60 | CXCL12 | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 30 | 69.9 (11.1) | 33.3 | ||||||||
[43] | Lee, 2008 | AD | 10 | 82.7 (8.4) | 70 | CCL27, CXCL1, CCL7, CXCL12, CXCL9 | BPC | Case–control | Plasma | 7 | NINCDS-ADRDA |
MCI | 25 | 72.1 (5.6) | 64 | ||||||||
HC | 19 | 71.4 (5.3) | 68.4 | ||||||||
[23] | Lee, 2018 | AD | 310 | 80.1 (7.2) | 44.8 | MCP-1 | Luminex xMAP™ | Prospective cohort | Plasma | 7 | NIA-AA |
MCI | 66 | 75.4 (8.2) | 47 | ||||||||
HC | 120 | 74.9 (7.8) | 45.8 | ||||||||
[41] | Leung, 2013 | AD | 117 | 76.2 (6.1) | 66.7 | IL-8, Eotaxin-1, IP-10, MCP-1 | Bio-Plex Luminex 200 | Prospective cohort | Plasma | 7 | NR |
MCI | 122 | 739 (5.6) | 49.2 | ||||||||
HC | 112 | 72.3 (6.7) | 53.6 | ||||||||
[68] | Li, 2008 | AD | 138 | 78.3 (5.9) | 39 | MIP-1α | ELISA | Case–control | Serum | 8 | DSM-III-R |
HC | 180 | 69.7 (4.2) | 31 | ||||||||
[31] | Liang, 2021 | AD | 28 | 78.3 (8.8) | 75 | IL-8, IP-10, MCP-1, RANTES, CCL3, CCL4, Eotaxin-1 | ECL | Cross-section | Plasma | 7 | NIA-AA |
MCI | 51 | 75.6 (8.6) | 78.4 | ||||||||
HC | 12 | 66.3 (5.9) | 75 | ||||||||
[69] | Llano, 2012 | AD | 15 | 22.1 (35.9) | 20 | IL-8 | ECL | Cross-section | CSF | 7 | NINCDS-ADRDA |
HC | 7 | 29.1 (3.5) | 29 | ||||||||
[70] | Lourenco, 2021 | AD | 14 | 67.8 (4.8) | 71 | IL-8, IP-10, MCP-1, RANTES, MIP-1α | ELISA | Cross-section | CSF | 7 | NR |
MCI | 14 | 71.6 (5.9) | 43 | ||||||||
HC | 25 | 67.8 (4.8) | 60 | ||||||||
[71] | Magaki, 2007 | AD | 7 | 79.14 (0.99) | 57 | IL-8 | ELISA | Case–control | Serum | 7 | DSM-IV/Petersen |
MCI | 31 | 75.1 (1.3) | 52 | ||||||||
HC | 21 | 73.1 (1.6) | 67 | ||||||||
[72] | Magdalinou, 2015 | AD | 26 | 62.8 (7.7) | 65.4 | MCP-1 | Immunoassays | Prospective cohort | CSF | 7 | NINCDS-ADRDA |
HC | 30 | 59.8 (9.8) | 50 | ||||||||
[29] | Marksteiner, 2011 | AD | 96 | 77.0 (0.8) | NR | IL-8, MCP-3, MIP1δ, MIP4, RANTES | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA/Petersen |
MCI | 44 | 73.5 (1.2) | NR | ||||||||
HC | 19 | 72.1 (1.3) | 42 | ||||||||
[73] | Mattsson, 2011 | AD | 25 | 74 (4) | 56 | IL-8, MCP-1 | ELISA | Cross-section | CSF | 7 | NINCDS-ADRDA |
MCI | 13 | 71 (4) | 62 | ||||||||
HC | 19 | 74 (5) | 53 | ||||||||
[33] | Mohd, 2017 | AD | 39 | 80.7 (6.4) | 56 | IL-8, CXCX1, CXCL10, MCP-1, MIP-1α | ELISA | Case–control | Serum | 7 | NINCDS-ADRDA |
HC | 39 | 72.1 (5.04) | 38 | ||||||||
[20] | Morgan, 2019 | AD | 262 | 75.9 (6.2) | NR | MCP-1, Eotaxin-1, MIP-1β | ECL | Case–control | Plasma | 7 | NINCDS-ADRDA |
MCI | 199 | 74.8 (5.8) | NR | ||||||||
HC | 259 | 72.9 (6.7) | NR | ||||||||
[74] | Nordengen, 2019 | AD | 27 | 67.6 (5.2) | 48 | MCP-1, fractalkine | QuickPlex SQ 120 system | Case–control | CSF | 7 | NIA-AA |
MCI | 40 | 66.6 (7.4) | 57 | ||||||||
HC | 36 | 61.1 (9.2) | 53 | ||||||||
[26] | O’Bryant, 2016 | AD | 79 | 76.1 (8.6) | 38 | CCL26, CCL17, CCL1 | ECL | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 65 | 71.2 (9.2) | 53 | ||||||||
[30] | Pedrini, 2017 | AD | 67 | 76 (7) | 66 | MCP-1, EOTAXN3, TARC | ECL | Prospective cohort | Plasma | 7 | NINCDS-ADRDA |
MCI | 39 | 75 (6) | 44 | ||||||||
HC | 559 | 69 (6) | 58 | ||||||||
[21] | Perea, 2018 | AD | 14 | 68 (4.2) | 64.3 | Fractalkine | ELISA | Case–control | CSF /serum | 7 | NINCDS-ADRDA |
MCI | 14 | 70 (3.52) | 64.3 | ||||||||
HC | 14 | 64 (2.9) | 50 | ||||||||
[75] | Porcellini, 2013 | AD | 291 | 75.1 (8) | NR | MCP-1 | BPC | Case–control | Plasma | 7 | NINCDS/ADRDA |
HC | 148 | 71.6 (4.7) | NR | ||||||||
[76] | Rauchmann, 2020 | AD | 188 | 74.7 (7.5) | 43 | IP-10 | ECL | Case–control | CSF | 7 | NINCDS-ADRDA/NIA-AA |
HC | 94 | 75.1 (7.1) | 38.3 | ||||||||
[77] | Reale, 2012 | AD | 38 | 73.8 (5.5) | 47.4 | MCP-1, RANTES | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 39 | 72.7 (4.8) | 53.8 | ||||||||
[78] | Rosén, 2014 | AD | 25 | 67.2 (17.5) | 64 | MCP-1 | ELISA | Case–control | CSF | 7 | NINCDS-ADRDA |
HC | 25 | 60.1 (8.7) | 64 | ||||||||
[79] | Schipke, 2019 | AD | 81 | 81.9 (7.8) | 67 | MCP-1 | ELISA | Case–control | Serum | 7 | NINCDS-ADRDA |
HC | 79 | 64.5 (2.7) | 35 | ||||||||
[80] | Shi, 2011 | AD | 50 | 68.1 (9.5) | 38 | Fractalkine | ELISA | Cross-section | CSF | 7 | NINCDS-ADRDA |
HC | 137 | 58.9 (18.4) | 45 | ||||||||
[42] | Soares, 2009 | AD | 19 | 81.0 (4.8) | 63.2 | RANTES, IL-8 | Luminex xMAP | Prospective cohort | Plasma | 7 | NINCDS-ADRDA |
HC | 22 | 76.5 (7.5) | 63.6 | ||||||||
[27] | Villarrea,2015 | AD | 28 | 81.9 (9.2) | 78.6 | I309, CCL17, CCL26, CCL3 | ECL | Cross-section | Serum | 7 | NINCDS-ADRDA |
MCI | 30 | 81.2 (7.8) | 66.7 | ||||||||
HC | 77 | 76.5 (6.7) | 64.9 | ||||||||
[81] | Wennström, 2015 | AD | 49 | 77.1 (6) | 76 | MCP-1, IL-8, IP-10 | ELISA | Case–control | CSF | 7 | DSM-III-R |
HC | 44 | 63.7 (10.3) | 52 | ||||||||
[24] | Westin, 2012 | AD | 47 | 74 (6) | 21 | CCL2, CCL11, CCL13, CCL26 | ELISA | Prospective cohort | CSF /plasma | 7 | NINCDS-ADRDA |
MCI | 52 | 64 (9) | 46 | ||||||||
HC | 30 | 72 (8) | 57 | ||||||||
[82] | Wu, 2015 | AD | 41 | 73.1 (9.4) | 65.9 | Fractalkine | ELISA | Case–control | Plasma | 7 | NINCDS |
HC | 40 | 63.0 (5.6) | 67.5 | ||||||||
[83] | Xu, 2021 | AD | 212 | 73.4 (8.5) | 55.7 | MCP-1 | Luminex xMAP™ | Case–control | Serum | 7 | NINCDS-ADRDA |
HC | 268 | 73.2 (8.7) | 55.2 | ||||||||
[84] | Yu, 2005 | AD | 11 | 65.5 (11.9) | 36 | IL8 | ELISA | Case–control | CSF /serum | 6 | NINCDS-ADRDA |
HC | 13 | 63.7 (12.8) | 46 | ||||||||
[85] | Zhang, 2008 | AD | 48 | 70 (9) | 40 | IL-8 | Immunobead-based multiplex | Case–control | CSF | 7 | NINCDS-ADRDA |
MCI | 12 | 71 (12) | 33 | ||||||||
HC | 95 | 63 (12) | 54 | ||||||||
[86] | Zhang, 2013 | AD | 24 | 77.9 (7.7) | 58.5 | MCP-1 | ELISA | Case–control | Plasma | 7 | NINCDS-ADRDA |
HC | 31 | 75.4 (9.5) | 48.4 | ||||||||
[87] | Zhu, 2017 | AD | 96 | 77.3 (7.3) | 62.5 | IL-8 | Luminex xMAP™ | Case–control | Serum | 7 | NINCDS-ADRDA |
MCI | 140 | 71.23 (8.1) | 47.9 | ||||||||
HC | 79 | 68.3 (6.0) | 51.9 |
Comparison between AD and HC in serum/plasma chemokine levels
Comparison | Chemokine | Sample | No of study | N | Main effect | Heterogeneity | Publication bias | |||
---|---|---|---|---|---|---|---|---|---|---|
RoM (95% CI) | P value | I2 (%) | P value | p for Begg’s | p for Egger’s | |||||
AD vs HC | CCL1 | Plasma/ serum | 3 | 199/696 | 1.56 (1.02–2.39) | 0.126# | 92.3 | < 0.001 | 1 | 0.51 |
CCL2 | 20 | 2017/1953 | 1.13 (0.92–1.39) | 0.726# | 98.7 | < 0.001 | 0.02 | 0.06 | ||
CCL3 | 5 | 244/321 | 1.36 (0.80–2.30) | 0.759# | 99.1 | < 0.001 | 1 | 0.72 | ||
CCL4 | 4 | 406/342 | 0.96 (0.82–1.12) | 1.701# | 37.9 | 0.148 | 0.31 | 0.09 | ||
CCL5 | 6 | 216/136 | 0.99 (0.62–1.60) | 2.73# | 97.8 | < 0.001 | 1 | 0.57 | ||
CCL7 | 4 | 277/261 | 1.19 (0.83–1.72) | 2.304# | 87 | 0.349 | 1 | 0.76 | ||
CCL11 | 3 | 301/284 | 1.17 (0.83–1.64) | 1.131# | 67.3 | 0.047 | 1 | 0.80 | ||
CCL15 | 3 | 207/78 | 1.29 (1.13–1.47) | 0.009# | 48.7 | 0.142 | 0.09 | 0.06 | ||
CCL17 | 4 | 140/175 | 1.31 (0.88–1.96) | 0.18 | 80 | 0.002 | 0.31 | 0.60 | ||
CCL18 | 2 | 238/193 | 1.05 (0.79–1.38) | 0.753 | 62.9 | 0.101 | - | - | ||
CCL19 | 2 | 43/50 | 1.71 (0.30–9.87) | 0.55 | 91.2 | 0.001 | - | - | ||
CCL22 | 2 | 111/59 | 1.04 (0.65–1.67) | 0.864 | 72.7 | 0.056 | - | - | ||
CCL26 | 3 | 174/701 | 0.81 (0.60–1.10) | 0.346# | 0 | 0.747 | 1 | 0.25 | ||
CCL27 | 3 | 58/87 | 1.34 (1.19–1.51) | < 0.001 | 0 | 0.368 | 0.30 | 0.55 | ||
CXCL1 | 4 | 92/108 | 1.28 (0.93–1.77) | 0.126 | 55.1 | 0.083 | 0.31 | 0.41 | ||
CXCL8 | 18 | 727/580 | 1.18 (0.85–1.62) | 0.966# | 98 | < 0.001 | 0.77a | 0.21a | ||
CXCL9 | 3 | 140/108 | 1.78 (1.39–2.28) | < 0.001 | 46.9 | 0.152 | 0.31 | 0.05 | ||
CXCL10 | 3 | 78/64 | 1.92 (1.03–3.58) | 0.039 | 99.4 | < 0.001 | 1 | 0.44 | ||
CXCL12 | 3 | 78/98 | 1.03 (0.85–1.24) | 0.727 | 91 | < 0.001 | 1 | 0.97 | ||
CX3CL1 | 4 | 148/131 | 1.20 (0.96–1.50) | 0.33# | 84.1 | < 0.001 | 1 | 0.51 | ||
AD vs MCI | CCL1 | 2 | 120/95 | 1.37 (1.17–1.59) | < 0.001 | 0 | 0.772 | - | - | |
CCL2 | 9 | 1026/573 | 1.13 (0.80–1.59) | 1.095# | 85.6 | < 0.001 | 0.60 | 0.53 | ||
CCL3 | 2 | 56/81 | 1.00 (0.86–1.16) | 2.982# | 0 | 0.722 | - | - | ||
CCL4 | 4 | 536/405 | 1.04 (0.95–1.14) | 1.227# | 0 | 0.704 | 0.31 | 0.11 | ||
CCL5 | 2 | 124/95 | 0.98 (0.77–1.25) | 2.7# | 52.5 | 0.147 | - | - | ||
CCL7 | 2 | 106/69 | 1.21 (0.96–1.53) | 0.3# | 0 | 0.843 | - | - | ||
CCL11 | 2 | 290/250 | 1.09 (0.96–1.24) | 0.489# | 32.1 | 0.225 | - | - | ||
CCL15 | 2 | 188/111 | 1.09 (1.00–1.19) | 0.135# | 0 | 0.996 | - | - | ||
CXCL8 | 6 | 271/302 | 1.13 (0.80–1.59) | 1.497# | 89.3 | < 0.001 | 1 | 0.08 | ||
CXCL9 | 2 | 46/61 | 2.29 (1.57–3.32) | < 0.001 | 25.8 | 0.246 | - | - | ||
CX3CL1 | 2 | 93/69 | 0.77 (0.62–0.96) | 0.05# | 0 | 0.938 | - | - | ||
MCI vs HC | CCL1 | 2 | 95/631 | 1.30 (0.66–2.54) | 1.356# | 90.6 | 0.001 | - | - | |
CCL2 | 13 | 655/665 | 1.07 (0.98–1.16) | 0.369# | 77.6 | < 0.001 | 0.50 | 0.412 | ||
CCL3 | 2 | 95/31 | 0.64 (0.22–1.92) | 1.827# | 91 | 0.001 | - | - | ||
CCL4 | 3 | 317/311 | 0.94 (0.83–1.07) | 1.059# | 1.8 | 0.361 | 1 | 0.51 | ||
CCL5 | 2 | 81/89 | 1.28 (0.50–3.23) | 1.281# | 79.7 | 0.027 | - | - | ||
CCL7 | 2 | 69/38 | 0.94 (0.73–1.22) | 1.971# | 42.1 | 0.189 | - | - | ||
CCL11 | 6 | 347/331 | 1.03 (0.97–1.1) | 0.933# | 0 | 0.824 | 1 | 0.49 | ||
CCL15 | 2 | 111/59 | 1.16 (1.01–1.35) | 0.117# | 0 | 0.654 | - | - | ||
CCL26 | 2 | 82/107 | 1.27 (0.63–2.57) | 1.768# | 41 | 0.193 | - | - | ||
CXCL8 | 7 | 340/194 | 1.05 (0.61–1.80) | 2.589# | 96.4 | < 0.001 | 0.45a | 0.79a | ||
CXCL9 | 2 | 61/52 | 1.01 (0.76–1.34) | 2.79# | 0 | 0.324 | - | - | ||
CX3CL1 | 2 | 69/77 | 2.02 (1.58–2.58) | < 0.001 | 19.2 | 0.266 | - | - | ||
AD vs HC | CCL2 | CSF | 12 | 310/338 | 1.19 (1.13–1.25) | < 0.001 | 0 | 0.81 | 0.84 | 0.73 |
CCL5 | 2 | 38/56 | 1.30 (0.66–2.57) | 0.451 | 48.3 | 0.164 | - | - | ||
CXCL8 | 10 | 260/308 | 1.22 (0.99–1.50) | 0.174# | 86.8 | < 0.001 | 0.59 | 0.85 | ||
CXCL10 | 5 | 295/231 | 1.05 (0.84–1.31) | 2.007# | 68.8 | 0.012 | 0.46 | 0.60 | ||
CXCL12 | 2 | 42/47 | 0.95 (0.62–1.46) | 0.803 | 83.8 | 0.013 | - | - | ||
CX3CL1 | 4 | 133/207 | 1.09 (0.93–1.28) | 0.933# | 51.6 | 0.102 | 0.73 | 0.71 | ||
MCI vs HC | CCL2 | 6 | 175/171 | 1.16 (1.05–1.29) | 0.012# | 59.2 | 0.031 | 0.26 | 0.39 | |
CXCL8 | 3 | 65/85 | 1.52 (0.70–3.29) | 0.585# | 96.2 | < 0.001 | 1 | 0.37 | ||
CXCL10 | 2 | 52/66 | 1.19 (0.48–2.97) | 2.103# | 92.6 | < 0.001 | - | - | ||
CX3CL1 | 3 | 72/70 | 1.27 (0.71–2.28) | 1.266# | 89.7 | < 0.001 | 1 | 0.63 | ||
AD vs MCI | CCL2 | 5 | 130/123 | 1.04 (0.90–1.19) | 1.893# | 56.3 | 0.058 | 1 | 0.33 | |
CXCL8 | 3 | 61/65 | 0.72 (0.38–1.37) | 0.96# | 94.7 | < 0.001 | 1 | 0.47 | ||
CXCL10 | 2 | 36/52 | 1.08 (0.56–2.08) | 2.454# | 76.2 | 0.04 | - | - | ||
CX3CL1 | 3 | 83/72 | 0.80 (0.51–1.27) | 1.044# | 81.1 | 0.005 | 1 | 0.33 |